Which generation of targeted drugs does Brigatinib belong to?

Brigatinib (Brigatinib) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is commonly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). It is a second-generation ALK inhibitor designed to overcome some of the challenges encountered in clinical treatment with first-generation drugs (such as crizotinib).

The first generationALKinhibitor crizotinib (Crizotinib) is currently used in the treatment ofALK PositiveNSCLC has achieved remarkable success, significantly extending patients' progression-free survival (PFS). However, with prolonged treatment, many patients develop resistance to crizotinib. This drug resistance is mainly due to the secondary mutation of the ALK gene and the rejection mechanism of tumor cells to the drug. In order to solve this problem, the second generation of ALK inhibitors came into being.

As a second-generation ALK inhibitor, brigatinib is designed to be more selective and potent, and can more effectively inhibit ALK and its mutant forms. Studies have shown that Brigatinibmutants resistant to crizotinib, such asL1196M, G1269A, S1206Y and F1174C etc. have significant inhibitory activity. It can not only penetrate the blood-brain barrier and have good curative effect on brain metastasis, but also effectively delay disease progression.

Clinical trial results of brigatinib show that its therapeutic effect is significantly better than that of crizotinib. In a phase III clinical trial called ALTA-1L, brigatinib (brigatinib) significantly prolonged the progression-free survival of patients compared with crizotinib, and also showed clear advantages in overall survival and objective response rate. Trials also show that brigatinibIt also has good efficacy in patients who have been treated with crizotinib and developed drug resistance.

Common side effects of brigatinib include nausea, diarrhea, headache, cough and fatigue. Although these side effects are relatively mild, individual differences and drug tolerance of patients still need to be paid attention to in clinical use.

In general, brigatinib (Brigatinib) as a second-generation ALK inhibitor, has demonstrated excellent results in the treatment of ALKpositive NSCLC, especially in crizotinib-resistant patients. With further research and clinical application, brigatinib is expected to bring new hope and treatment options to more lung cancer patients.